Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 2

Completed

Conditions: Glioblastoma
Gliosarcoma
Malignant Gliomas

First Posted Date: 2005-09-14

Last Posted Date: 2010-03-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 23

Registration Number: NCT00165477

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 1 locations

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Phase 3

Active, not recruiting

Conditions: DS Stage I Multiple Myeloma
Smoldering Multiple Myeloma
DS Stage II Multiple Myeloma
DS Stage III Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Drug: Melphalan
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Placebo Administration

First Posted Date: 2005-06-14

Last Posted Date: 2024-11-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 460

Registration Number: NCT00114101

Locations: 🇺🇸
Carle BroMenn Medical Center, Normal, Illinois, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 137 locations

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

Phase 1

Completed

Conditions: Smoldering Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma
Stage I Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Radiation: total marrow irradiation
Drug: melphalan
Procedure: peripheral blood stem cell transplantation
Biological: filgrastim
Genetic: fluorescence in situ hybridization
Genetic: cytogenetic analysis
Drug: cyclophosphamide
Procedure: autologous-autologous tandem hematopoietic stem cell transplantation
Drug: lenalidomide

First Posted Date: 2005-06-03

Last Posted Date: 2021-03-01

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 54

Registration Number: NCT00112827

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1

Phase 2

Terminated

Conditions: Complex Regional Pain Syndrome, Type I

Interventions: Drug: lenalidomide
Drug: Placebo

First Posted Date: 2005-05-04

Last Posted Date: 2013-08-28

Lead Sponsor: Celgene Corporation

Target Recruit Count: 184

Registration Number: NCT00109772

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
Washington University Pain Mgmt Ctr, St. Louis, Missouri, United States
🇺🇸
Lehigh Valley Hospital, Allentown, Pennsylvania, United States

and more 24 locations

Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Childhood Myelodysplastic Syndromes
de Novo Myelodysplastic Syndromes
Previously Treated Myelodysplastic Syndromes
Refractory Anemia
Refractory Anemia With Excess Blasts
Refractory Cytopenia With Multilineage Dysplasia
Secondary Myelodysplastic Syndromes
Unspecified Childhood Solid Tumor, Protocol Specific
Refractory Anemia With Ringed Sideroblasts

Interventions: Drug: lenalidomide

First Posted Date: 2005-03-04

Last Posted Date: 2014-06-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00104962

Locations: 🇺🇸
COG Phase I Consortium, Arcadia, California, United States

Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors

Phase 1

Completed

Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor
Childhood Central Nervous System Germ Cell Tumor
Childhood Choroid Plexus Tumor
Childhood Craniopharyngioma
Childhood Ependymoblastoma
Childhood Grade I Meningioma
Childhood Grade II Meningioma
Childhood Grade III Meningioma
Childhood High-grade Cerebellar Astrocytoma
Childhood High-grade Cerebral Astrocytoma

Interventions: Drug: lenalidomide
Procedure: perfusion-weighted magnetic resonance imaging
Procedure: diffusion-weighted magnetic resonance imaging
Other: laboratory biomarker analysis

First Posted Date: 2005-01-07

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT00100880

Locations: 🇺🇸
Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States

Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma

Phase 3

Active, not recruiting

Conditions: DS Stage I Multiple Myeloma
DS Stage II Multiple Myeloma
DS Stage III Multiple Myeloma

Interventions: Drug: Dexamethasone
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Drug: Thalidomide

First Posted Date: 2004-12-08

Last Posted Date: 2024-12-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 452

Registration Number: NCT00098475

Locations: 🇺🇸
OSF Saint Anthony's Health Center, Alton, Illinois, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Huntsville Hospital, Huntsville, Alabama, United States

and more 135 locations

Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer

Phase 2

Completed

Conditions: Kidney Cancer

First Posted Date: 2004-11-10

Last Posted Date: 2013-01-17

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00096525

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Biological: rituximab
Drug: lenalidomide

First Posted Date: 2004-11-09

Last Posted Date: 2017-07-11

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 45

Registration Number: NCT00096044

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: dexamethasone
Drug: lenalidomide

First Posted Date: 2004-09-09

Last Posted Date: 2017-02-20

Lead Sponsor: Vaishali Sanchorawala

Target Recruit Count: 82

Registration Number: NCT00091260

Locations: 🇺🇸
Cancer Research Center at Boston Medical Center, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy